These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 31131678

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
    Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV.
    Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
    Eksteen B, Bowlus CL, Montano-Loza AJ, Lefebvre E, Fischer L, Vig P, Martins EB, Ahmad J, Yimam KK, Pockros PJ, Feld JJ, Minuk G, Levy C.
    Hepatol Commun; 2021 Mar; 5(3):478-490. PubMed ID: 33681680
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.
    Tabibian JH, Gossard A, El-Youssef M, Eaton JE, Petz J, Jorgensen R, Enders FB, Tabibian A, Lindor KD.
    Am J Ther; 2017 Mar; 24(1):e56-e63. PubMed ID: 24914504
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort.
    Bakhshi Z, Hilscher MB, Gores GJ, Harmsen WS, Viehman JK, LaRusso NF, Gossard AA, Lazaridis KN, Lindor KD, Eaton JE.
    J Gastroenterol; 2020 May; 55(5):523-532. PubMed ID: 31932891
    [Abstract] [Full Text] [Related]

  • 12. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning.
    Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN.
    Hepatology; 2020 Jan; 71(1):214-224. PubMed ID: 29742811
    [Abstract] [Full Text] [Related]

  • 13. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
    Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U.
    J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Short-term prognostic factors for primary sclerosing cholangitis.
    Watanabe T, Hirano K, Tada M, Isayama H, Mizuno S, Arizumi T, Toda N, Sugawara Y, Kokudo N, Koike K.
    J Hepatobiliary Pancreat Sci; 2015 Jun; 22(6):486-90. PubMed ID: 25826613
    [Abstract] [Full Text] [Related]

  • 18. A pilot study of etanercept in the treatment of primary sclerosing cholangitis.
    Epstein MP, Kaplan MM.
    Dig Dis Sci; 2004 Jan; 49(1):1-4. PubMed ID: 14992426
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.